BioInfra Life Science Inc. (XKON:266470)

Market Cap	2.01B -74.6%
Revenue (ttm)	1.78B +27.5%
Net Income	-3.59B
EPS	-266.28
Shares Out	21.67M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	80,186
Average Volume	28,154
Open	121.00
Previous Close	106.00
Day's Range	91.00 - 121.00
52-Week Range	91.00 - 455.00
Beta	-0.35
RSI	26.32
Earnings Date	n/a

About BioInfra Life Science

BioInfra Life Science Inc., a healthcare company, develops cancer gene treatments and technologies that monitor the possibility of metastasis and recurrence in blood for cancer patients in South Korea. It provides cancer screening test technology service, cancer biomarker research, in-vitro diagnostics medical devices, and targeted drug delivery systems for cancer treatment. The company was founded in 2001 and is headquartered in Seoul, South Korea.

• Industry: Surgical and Medical Instruments and Apparatus
• Founded: 2001
• Country: South Korea
• Stock Exchange: Korea New Exchange
• Ticker Symbol: 266470

Financial Performance

In 2019, BioInfra Life Science's revenue was 1.87 billion, an increase of 20.83% compared to the previous year's 1.55 billion. Losses were -3.28 billion, -13.88% less than in 2018.